SS Innovations International Inc. Common Stock

SS Innovations International has supported the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo using the SSi Mantra 3.0 surgical robotic system. The program began with a robotic-assisted LIMA takedown performed by SS Innovations founder and Chairman Dr. Sudhir Srivastava alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva, and Kings Hospital has completed more than 25 robotic procedures in three weeks. SS Innovations reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter, with second-quarter revenue of $13.9 million and robotic procedures up 143% year over year to 2,528. The company's next major corporate milestone is regulatory expansion, as it pursues U.S. FDA clearance and European CE marking for the SSi Mantra system.

SS Innovations International announced that its SSi Mantra surgical robotic system was used in more than 50 procedures in a single day at Mohak Bariatrics and Robotics in Indore, India, highlighting growing clinical adoption. The company has installed 224 SSi Mantra systems across 12 countries, with 30 systems installed in the second quarter of 2026, exceeding the 25 systems modeled by analysts. Quarterly revenue reached $13.9 million, up 39% year over year, while system sales increased 41% to $12.4 million. FDA review of the SSi Mantra 510(k) application is expected by the end of the first quarter of 2027, and European CE marking is targeted for the end of 2026. The company's progress in India provides a strong commercial base as it pursues entry into the U.S. and European markets.

SS Innovations International is expanding its presence in the global surgical robotics market through its proprietary SSi Mantra robotic surgery platform. More than 200 SSi Mantra systems have been installed worldwide, supporting over 12,000 robotic procedures across more than 170 surgical indications. The company's strategy combines world-class robotic systems, including telesurgery capabilities, with affordability, physician training, and international market expansion. SS Innovations continues pursuing U.S. FDA clearance and European regulatory approvals while building its installed base internationally. Growing demand for minimally invasive surgery and broader access to robotic procedures continues to create opportunities for emerging high-tech medical technology companies.

SS Innovations International announced that its subsidiary, the SS International Centre for Robotics Surgery, graduated its inaugural class in cardiac robotic surgery training. The class comprised 33 participants from seven countries and featured 16 international faculty members. The course provided hands-on training with the SSi Mantra surgical robotic system, covering procedures such as totally endoscopic coronary artery bypass and mitral valve surgery.

SS Innovations International has appointed Sarah Romano as Chief Financial Officer, effective August 3, 2026. Romano brings over two decades of finance experience in the medical technology and life sciences sectors, most recently serving as CFO of Vicarious Surgical. She previously held CFO roles at Entero Therapeutics and Kiora Pharmaceuticals, where she led capital raising, strategic transactions, SEC reporting, and investor relations. Romano began her career as an auditor at PricewaterhouseCoopers and is a licensed CPA in Massachusetts.

IBN has initiated coverage of SS Innovations International, a developer of surgical robotic technologies. SS Innovations' flagship product is the SSi Mantra surgical robotic system, which has been used in more than 11,700 surgeries worldwide. The company has engaged IBN to assist with its corporate communications strategy, leveraging IBN's investor-focused distribution network of over 5,000 syndication outlets. SS Innovations also offers complementary technologies including the SSi Mudra instruments, the SSi MantrAsana tele-surgeon console, and the SSi Maya mixed-reality platform.

SS Innovations International announced that its subsidiary, the SS International Centre for Robotics Surgery, has graduated its first class in a specialized cardiac robotic surgery training course. The inaugural class comprised 33 participants from seven countries who received classroom instruction and hands-on learning using the SSi Mantra surgical robotic system at the company's headquarters in Gurugram, India. The course featured 16 international faculty members and covered procedures such as totally endoscopic coronary artery bypasses and mitral valve surgery through live demonstrations, hands-on training, and scientific discussions. SSICRS's ongoing training program will consist of condensed five-day courses across multiple surgical specialties, leveraging the SSi Mantra platform.

ABIVAX Société Anonyme surged 38.6% after reporting positive results from Part 2 of its Phase 3 ABTECT Maintenance trial of Obefazimod for moderate-to-severe ulcerative colitis, showing meaningful clinical benefits in hard-to-treat patients and strengthening the drug's long-term safety profile. The company also announced a $600 million underwritten public offering of American Depositary Shares. ProMIS Neurosciences rose 22.4% with no specific news, as investors await 6-month interim data from the PRECISE-AD Phase 1b trial in early Q3 2026. Cuprina Holdings gained 45.7% following last month's FDA clearance of its MEDIFLY Maggots for wound debridement. First Tracks Biotherapeutics climbed 18.3%, with top-line data from its ANB033 celiac disease trial expected in Q4 2026. SS Innovations International advanced 17.9% after winning an industry award and reporting 11,719 cumulative procedures with its SSi Mantra surgical robotic system.

SS Innovations International has been named the winner of the Outstanding Company category at the 2026 Surgical Robotics Industry Awards. The award recognizes excellence in innovation, commercial success, industry leadership and positive societal impact. The company says the honor reflects growing adoption of its SSi Mantra surgical robotic system, which is gaining traction for its advanced technology, user-friendly design, training capabilities and cost efficiency. As of June 22, 2026, 11,719 multi-specialty procedures have been performed using the SSi Mantra system, including 612 cardiac procedures, 175 telesurgeries and 212 pediatric surgeries. Approximately 2,100 physicians have been trained on the platform, which has been used for more than 170 procedure types and has received regulatory approval in 14 countries.